Short Interest in Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Decreases By 49.9%

by · The Markets Daily

Protagenic Therapeutics, Inc. (NASDAQ:PTIX – Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 49,300 shares, a drop of 49.9% from the November 30th total of 98,400 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 237,900 shares, the days-to-cover ratio is presently 0.2 days.

Protagenic Therapeutics Stock Performance

PTIX stock traded down $0.06 during midday trading on Friday, reaching $0.48. 358,941 shares of the company traded hands, compared to its average volume of 129,951. The firm has a market capitalization of $3.39 million, a price-to-earnings ratio of -0.37 and a beta of 0.21. The business has a 50 day moving average of $0.60 and a 200-day moving average of $0.68. Protagenic Therapeutics has a 52-week low of $0.44 and a 52-week high of $1.87.

Protagenic Therapeutics Company Profile

(Get Free Report)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.

Further Reading